Condition

Clear Cell Renal Cell Carcinoma clinical trials and research

• 32Clinical trials
• 1New in 30 days
• 10Countries

Newest Clear Cell Renal Cell Carcinoma clinical trials

All recruiting trials (32)

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• Immune cell therapy for advanced clear cell kidney cancer

  This study tests a patient's own tumor-infiltrating lymphocytes (TIL) therapy, given after conditioning with chemotherapy and then interleukin-2, in adults with advanced clear cell renal cell carcinoma who have tried prior treatments.

  Recruiting at 2 sites Phase 1 Hangzhou Huasai Biomedicine Co., Ltd. · Beijing and 1 other locations · NCT07770802

• Theranostic pair labeled PD-32766D/T in CA9-positive clear cell kidney cancer

  This study tests a matching diagnostic agent PD-32766D and a therapeutic agent PD-32766T in adults with CA9-expressing clear cell renal cell carcinoma to see if the treatment is safe and shows signs of effect.

  Recruiting Phase 1 PeptiDream Inc. · Omaha, Nebraska · NCT07688187

• LNK001 CAR T therapy in advanced clear cell kidney cancer

  This study tests a CAR T-cell therapy called LNK001 to see if it can help people with advanced clear cell renal cell carcinoma after other treatments.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07564232

• Neoadjuvant immunotherapy with botensilimab and balstilimab for high-risk non-metastatic clear cell RCC

  This trial tests whether giving botensilimab and balstilimab before kidney tumor surgery is safe and helps patients with high‑risk non‑metastatic clear cell RCC proceed to nephrectomy.

  Recruiting at 5 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 4 other locations · NCT07516366

• SLC-3010 plus axitinib versus axitinib alone for second-line treatment of advanced clear cell kidney cancer

  This trial tests whether adding SLC-3010 to axitinib works better than axitinib alone for adults with locally advanced or metastatic clear cell kidney cancer who need second-line treatment.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07469683

• Iparomlimab and Tuvonralimab plus lenvatinib before kidney-sparing surgery for clear cell kidney cancer

  This will test whether giving Iparomlimab and Tuvonralimab (QL1706) together with lenvatinib before surgery helps people with localized clear cell kidney cancer (T1–T2) who need but may have difficulty getting kidney-preserving surgery because of a high R.E.N.A.L. score.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou · NCT07389629

• NEO-811 for advanced or metastatic clear cell kidney cancer

  This study will try the experimental oral drug NEO-811 in people with locally advanced or metastatic clear cell kidney cancer who have progressed on or refused standard treatments.

  Recruiting at 16 sites Phase 1 Neomorph, Inc · Duarte, California and 15 other locations · NCT07300241

• PF-08634404 alone and with other anticancer medicines for adults with advanced kidney cancer.

  This tests whether PF-08634404, given alone or with other cancer medicines, is safe and helps adults with locally advanced or metastatic kidney cancer who have not had prior systemic treatment.

  Recruiting at 157 sites Phase 1/2 Pfizer · Phoenix, Arizona and 182 other locations · NCT07227415

• Cemiplimab alone or with fianlimab after stereotactic body radiation for oligometastatic clear cell kidney cancer

  This trial will test whether giving cemiplimab alone or with fianlimab after stereotactic body radiation helps people with oligometastatic clear cell kidney cancer stay free of recurrence longer.

  Recruiting Phase 2 University of Oklahoma · Oklahoma City, Oklahoma · NCT07223541

• Bone metastasis in clear cell kidney cancer: cabozantinib plus nivolumab feasibility and bone microenvironment study

  This study tests whether cabozantinib with nivolumab can be given safely to people with clear cell renal cell carcinoma that has spread to bone and helps us see how bone immune cells respond.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07187869

• Neoadjuvant belzutifan, pembrolizumab, or both for clear cell kidney cancer

  We will see if giving belzutifan alone, pembrolizumab alone, or both before kidney surgery helps shrink locally advanced clear cell kidney cancer.

  Recruiting at 2 sites Phase 2 M.D. Anderson Cancer Center · Ann Arbor, Michigan and 1 other locations · NCT07187778

• Zanzalintinib with a bone-strengthening agent for metastatic clear cell RCC with bone metastases

  This phase 2 trial tests zanzalintinib plus a bone-strengthening agent in adults with metastatic clear cell renal cell cancer that has spread to bone and progressed after 1–3 prior therapies, including IO therapy.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT07043608

• Adding CBM588 to pembrolizumab after surgery for kidney cancer

  This trial tests whether adding CBM588 to pembrolizumab after kidney cancer surgery helps prevent recurrence compared with pembrolizumab alone.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07037004

• Belzutifan vs active surveillance for indolent metastatic clear cell RCC

  This study tests whether belzutifan can help control disease in adults with metastatic clear cell RCC who are candidates for active surveillance and have not had prior systemic therapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07023432

• Combination of XL092 and Immunotherapy for Advanced Clear Cell Kidney Cancer

  This study is testing if a new drug called XL092, alone or with another treatment called nivolumab, can help people with advanced clear cell kidney cancer who haven't responded well to previous therapies.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · La Jolla, California and 4 other locations · NCT06863311

• Testing a new drug for advanced solid tumors that express c-Kit

  This study is testing a new drug for people with advanced solid tumors that have a specific marker called c-Kit to see if it is safe and how well it works.

  Recruiting at 4 sites Phase 1 Novelty Nobility, Inc. · Ann Arbor, Michigan and 4 other locations · NCT06805825

• 89Zr-TLX250 for imaging clear cell kidney cancer

  This study is testing a new imaging agent called 89Zr-TLX250 to see if it can help find clear cell kidney cancer in adults who have uncertain kidney masses before they have surgery.

  Recruiting Phase 3 Telix Pharmaceuticals (Innovations) Pty Limited · Beijing and 7 other locations · NCT06750419

• Combining Toripalimab and JS004 for treating advanced kidney cancer

  This study is testing if a new combination of two drugs, toripalimab and JS004, can help people with advanced kidney cancer do better than the usual treatment they would receive.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06690697

• Combining Tivozanib with Pembrolizumab for Kidney Cancer Treatment

  This study is testing if adding a cancer drug called tivozanib to the immunotherapy pembrolizumab can help people with high-risk kidney cancer live longer and feel better after their surgery.

  Recruiting at 409 sites Phase 3 Alliance for Clinical Trials in Oncology · Phoenix, Arizona and 428 other locations · NCT06661720

• Using 68Ga-NY104 PET/CT to guide radiation therapy for advanced kidney cancer

  This study is testing if a special imaging technique can help doctors better plan radiation therapy for people with advanced kidney cancer to improve their treatment outcomes.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06613269

• Evaluating a new imaging method for clear cell renal cell carcinoma

  This study is testing a new imaging method using a special probe to see if it can better help doctors diagnose clear cell renal cell carcinoma in Chinese patients compared to the standard imaging method.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT06519760

• New imaging method for detecting recurrent kidney cancer after surgery

  This study is testing a new imaging method to see if it can better detect kidney cancer returning after surgery compared to the usual imaging techniques.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT06447103

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

• Predicting disease-free survival in kidney cancer using deep learning and CT scans

  This study is testing a new computer model that uses CT scans to see if it can help predict how long patients with localized kidney cancer will be free of disease after surgery.

  Recruiting First Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT06088134

• Combination treatment for advanced clear cell kidney cancer

  This study is testing a new combination of treatments for people with advanced clear cell kidney cancer to see if it is safe and effective.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05663710

• Evaluating AB521 for kidney cancer and other solid tumors

  This study is testing a new treatment called casdatifan, alone and with other medications, to see if it helps people with advanced kidney cancer and other solid tumors feel better.

  Recruiting at 24 sites Phase 1 Arcus Biosciences, Inc. · Birmingham, Alabama and 24 other locations · NCT05536141

• Treatment of advanced clear cell kidney cancer with XmAb®819

  This study is testing a new drug called XmAb®819 to see if it’s safe and effective for people with advanced clear cell kidney cancer who haven't responded to other treatments.

  Recruiting at 26 sites Phase 1 Xencor, Inc. · Phoenix, Arizona and 25 other locations · NCT05433142

• Identifying new biomarkers for clear cell renal cell carcinoma

  This study is trying to find new markers in the blood that can help doctors diagnose clear cell kidney cancer earlier and better by comparing them in patients with the cancer and healthy people.

  Recruiting Qianfoshan Hospital · Jinan · NCT05214885

• Imaging study using [18F]PT2385 for renal cell carcinoma

  This study is testing a new imaging method using [18F]PT2385 to see if it can help understand tumor characteristics in people with renal cell carcinoma.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT04989959

• Detecting urinary exosomes in patients with clear cell renal cell carcinoma

  This study is testing a new way to find cancer markers in urine from patients with clear cell kidney cancer to see if it can help with early diagnosis.

  Recruiting Centre Hospitalier Universitaire de Saint Etienne · Saint-Etienne · NCT04053855

Related topics

Quick answers

How many Clear Cell Renal Cell Carcinoma clinical trials are recruiting right now?

32, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in United States (20 trials), China (11 trials), Australia (3 trials), Spain (3 trials), South Korea (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 13, Phase 1: 10, Phase 3: 2, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →